Mulfinya (Fingolimod)

Fingolimod, the active ingredient in Mulfinya, is a sphingosine‑1‑phosphate receptor modulator presented as an oral tablet for oral use. It is indicated for the treatment of relapsing‑remitting multiple sclerosis in adult patients, helping to reduce the frequency of clinical relapses and to slow the accumulation of disability.

GNH USA supplies Mulfinya as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels, ensuring quality and traceability for global markets.

Mulfinya (fingolimod) is used in the management of multiple sclerosis, a chronic autoimmune disease of the central nervous system.

- Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression. - Active secondary progressive multiple sclerosis: decreases disease activity in patients with superimposed relapses. - Clinically isolated syndrome at high risk of conversion: delays onset of clinically definite multiple sclerosis.

Mulfinya may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Cough: non‑productive. - Fatigue: persistent tiredness. - Lymphopenia: reduced lymphocyte count. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial infections. - Cardiac arrhythmia: bradycardia or atrioventricular block. - Macular oedema: visual disturbances requiring ophthalmic evaluation. - Severe liver injury: marked transaminase elevation or hepatitis. - Progressive multifocal leukoencephalopathy: rare viral CNS infection.

Before initiating Mulfinya, several safety considerations should be addressed.

- Cardiac monitoring: obtain baseline ECG and observe heart rate during first dose. - Infection screening: assess for active infections and vaccinate appropriately before treatment. - Liver function: evaluate baseline hepatic enzymes and monitor periodically. - Ophthalmic assessment: perform baseline eye exam and repeat if visual symptoms occur. - Pregnancy contraindication: avoid use in pregnant women; ensure effective contraception. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mulfinya can interact with other medicines, requiring careful management.

Major Interactions (Avoid):\n- CYP4F2 inhibitors: may increase fingolimod exposure. - Strong immunosuppressants: heightened risk of infections. - Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antihypertensives: potential additive blood pressure effects. - Antiplatelet agents: increased bleeding tendency. - CYP3A4 inducers: may reduce fingolimod plasma levels.